Felix Biotechnology announces initiation of a Phase 1/2 study at Yale for targeted phage therapy in the treatment of P. aeruginosa infections
Felix Biotechnology announced the initiation of CYPHY, a Phase 1/2 investigator-initiated single center trial at Yale University for targeted phage therapy YPT-01 in the treatment of chronic P. aeruginosa infections in cystic fibrosis. This double-blind, […]
